Stemming from world-class research
Renovos, based in Southampton, UK, is commercialising the world-class research undertaken at the University of Southampton and draws on over 50 years of combined expertise in skeletal stem cells, translational orthopaedic research and materials for tissue repair.
This pioneering work is led by our two academic founders:
- Prof Richard Oreffo, leader of the Bone and Joint Research Group and Director of the University’s Centre for Human Development, Stem Cells and Regeneration
- Dr Jon Dawson, Research Fellow and technology expert in biomaterials and nanoclays
and supported by the expertise of the whole orthopaedic regenerative medicine research team.
Transforming orthopaedics and regenerative medicine through pioneering use of nanoclay gels stemming from world-class stem cell research
Co-founder / Executive Chairman
James has extensive corporate commercial experience including a range of international management positions with Zeneca Agrochemicals and led a major turnaround while on the board of Spectris plc. Over the last 15 years he has focused on the bioscience SME sector, both as an investor while chairman of Hygea VCT and as CEO of several SMEs focused on imaging, drug delivery, telemedicine and cell culture. James brings a wealth of invaluable start-up, investment, governance and commercialisation experience to Renovos Biologics Ltd., essential to the role of Chairman.
Dr Agnieszka Janeczek
Co-founder / Business Development and Operations
Agnieszka has a PhD and Master’s degree in biotechnology/regenerative medicine with proven track record of working on stem cells, drug delivery systems and nanomaterials so brings over a decade of technical expertise to the company. Since then Agnieszka has gathered relevant market research to define the development and commercialisation pathways for our different products as supported by the Innovate UK and HEFCE-funded SETsquared Business Incubator’s Innovation to Commercialisation of University Research (ICURe) and University of Southampton Science Park Catalyst Programmes. Agnieszka drives business development activities and operations, and oversees development of our product portfolio.
Dr Simon Sinclair
Simon has over 15 years’ pharma and medtech industry experience in translational medicine, clinical development, medical affairs, medical safety, vigilance and real-world evidence, in both people management and governance roles. He has held positions at corporates such as DePuy Synthes, Johnson and Johnson Medical Devices, and Merck & Co. Inc. As a NED, Simon brings his extensive orthopaedic product development, evidence generation and commercial expertise to the Renovos team.
Prof Richard Oreffo
Co-founder / CSO
Richard is Professor of Musculoskeletal Science and co-founder/Director of the Centre for Human Development, Stem Cells and Regeneration. He leads a multidisciplinary research group focused on developing strategies to repair bone & cartilage; with translation a key personal driver. To achieve these goals, he has brought together and developed teams of clinicians/life scientists over the last twenty years. He has published >285 peer-reviewed papers including breakthrough publications on skeletal stem cells and nanotopography, bone regeneration as well as epigenetics, holds 6 patents and generated over £24m as PI/co-I in research grant income since 2000. As CSO Richard is able to leverage his extensive professional network and profile in the field of regenerative medicine and will determine scientific direction of Renovos.
Dr Jon Dawson
Co-founder / Development Lead
Jon brings over a decade of expertise in clay materials from initial work for his doctorate on clay materials at UoS (2007) to his current EPSRC Early Career Research Fellowship to develop clay-based applications to regenerative medicine. Jon has published in several high-impact journals in the field of regenerative medicine (>450 citations) and is recognised for his world-leading expertise in clay-gel research. As such, Jon drives the nanoclay development studies for Renovos.
Providing next-generation regenerative medicine
Innovative research has led to spectacular progress in the field of stem cell and biomaterial products helping the world’s ageing populations remain active for longer.
Please contact us for more information on our technologies or investment opportunities at email@example.com